Therapeutic Potential of Targeting PI3K/AKT Pathway in Treatment of Colorectal Cancer: Rational and Progress

Afsane Bahrami(Mashhad University of Medical Sciences), Majid Khazaei(Mashhad University of Medical Sciences), Malihe Hasanzadeh(Mashhad University of Medical Sciences), Soodabeh Shahidsales(Mashhad University of Medical Sciences), Mona Joudi Mashhad(Mashhad University of Medical Sciences), Marjaneh Farazestanian(Mashhad University of Medical Sciences), Hamid Reza Sadeghnia(Mashhad University of Medical Sciences), Majid Rezayi(Mashhad University of Medical Sciences), Mina Maftouh(Mashhad University of Medical Sciences), Seyed Mahdi Hassanian(Mashhad University of Medical Sciences), Amir Avan(Mashhad University of Medical Sciences)
Journal of Cellular Biochemistry
February 23, 2017
10.1002/jcb.25950
Cited by 243

Abstract

PI3K/AKT/mTOR signaling pathway is one of the key dysregulated pathways in different tumor types, including colorectal cancer (CRC). Activation of this pathway is shown to be related with cellular transformation, tumor progression, cell survival, and drug resistance. There is growing body of data evaluating the value of PI3K/AKT/mTOR inhibitors in CRC (e.g., BEZ235, NVP-BEZ235, OSI-027, everolimus, MK-2206, KRX-0401, BYL719, and BKM120). This report summarizes the current knowledge about PI3K/AKT pathway and its cross talk with ERK/MAPK and mTOR pathways with particular emphasis on the value of targeting this pathway as a potential therapeutic target in treatment of colorectal cancer. J. Cell. Biochem. 119: 2460-2469, 2018. © 2017 Wiley Periodicals, Inc.

Related Papers

No related papers found

Powered by citation graph analysis